2025-04-22 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Report

**0. Key Figures & Initial Analysis:**

TEVA's cumulative return significantly lags behind the S&P 500 (VOO).  While the provided data shows a positive return for TEVA, the substantial underperformance relative to the market warrants further investigation.  The company's recent negative EPS figures also raise concerns.  A deeper dive into the financial statements and market context is needed to form a comprehensive opinion.


**1. Performance Comparison:**

Teva Pharmaceutical Industries Ltd ADR is a generic drug manufacturer and developer.

* **TEVA Cumulative Return:** 30.57%
* **VOO (S&P 500) Cumulative Return:** 72.42%
* **Return Difference:** -41.9%  (TEVA underperformed VOO by 41.9%).
* **Relative Divergence:** 58.6% (This indicates TEVA's current underperformance is relatively lower than the minimum underperformance observed historically.)

The Alpha and Beta analysis in the provided table shows significant volatility and underperformance against the market (negative Alpha) over several periods.  High Beta values (particularly in 2015-2017) suggest TEVA is highly sensitive to market fluctuations.  However, recent years show a decreasing beta and a significant increase in CAGR.


**2. Recent Price Movement:**

* **Closing Price:** $13.31
* **5-Day Moving Average:** $13.52
* **20-Day Moving Average:** $14.42
* **60-Day Moving Average:** $16.11

The closing price is below all three moving averages, suggesting a possible downtrend.  The recent price drop of -2.49%  indicates a short-term negative momentum.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4082 (Medium Risk)
* **RSI:** 31.20 (Suggests oversold conditions, potential bounce)
* **PPO:** -0.246 (Negative, confirming bearish trend)
* **Delta_Previous_Relative_Divergence:** +4.2 (Short-term upward movement)
* **Expected Return:** -54.5% (This indicates a substantial negative expectation. This is a significant factor that needs to be addressed in a longer-term analysis)

The significant price drop (-2.49%) warrants consideration of potential underlying news or events impacting the stock price.  The negative expected return needs further clarification and context, particularly considering it's compared against a long-term investment horizon exceeding 2 years.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-06 | -$0.39 | $4.33B       |
| 2024-07-31 | -$0.75 | $4.16B       |
| 2024-05-08 | -$0.12 | $3.82B       |
| 2023-11-09 | $0.07  | $3.85B       |
| 2024-02-12 | $0.06  | $3.85B       |

Recent earnings show a mixed performance.  While revenue is relatively stable, EPS has been largely negative in recent quarters, indicating profitability concerns. This needs further investigation, looking into potential factors contributing to these losses.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-12-31 | $4.23B      | 50.15%        |
| 2024-09-30 | $4.33B      | 49.60%        |
| 2024-06-30 | $4.16B      | 48.61%        |
| 2024-03-31 | $3.82B      | 46.37%        |
| 2023-12-31 | $4.46B      | 54.18%        |

Revenue fluctuates moderately while profit margins also show some instability.  The high profit margin in 2023-12-31 contrasts with lower margins in 2024, suggesting further analysis of operational efficiency and cost management.

**Capital and Profitability:**

| Quarter     | Equity      | ROE           |
|-------------|-------------|---------------|
| 2024-12-31 | $5.37B      | -4.04%        |
| 2024-09-30 | $6.07B      | -7.21%        |
| 2024-06-30 | $6.36B      | -13.30%       |
| 2024-03-31 | $7.28B      | -1.91%        |
| 2023-12-31 | $7.51B      | 5.72%         |

Negative ROE for most recent quarters signals a serious concern, suggesting the company is not generating sufficient returns on its equity.  This needs urgent attention, requiring analysis of the underlying causes and potential remedial actions.


**6. Overall Analysis:**

TEVA exhibits significant underperformance compared to the S&P 500, with a concerning negative expected return.  While some technical indicators suggest oversold conditions and potential short-term upward momentum, the negative EPS, declining ROE, and fluctuating profit margins raise considerable concerns about the company's financial health and long-term prospects.  Further investigation into the causes of the negative EPS and ROE, as well as a more detailed analysis of the -54.5% expected return, is crucial before making any investment decisions.  The substantial volatility highlighted by the beta values also suggests a higher risk profile.  While recent positive CAGR is promising, it should be considered in the context of the overall financial picture and market conditions.
